Adrenomed AG is a German privately-financed, clinical stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials. https://adrenomed.com/
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.
CEL-SCI's lead investigational therapy, Multikine®* (Leukocyte Interleukin, Injection), is currently being developed as a potential therapeutic agent aimed at harnessing the patient's own immune system to produce an anti-tumor response. Data from Phase I and Phase II clinical trials suggest that Multikine simulates the activities of a healthy person's immune system, enabling it to use the body's own anti-tumor immune response. Multikine is the trademark we have registered for this investigational therapy, and this proprietary name is subject to review by the U.S. Food and Drug Administration, or FDA, in connection with our future anticipated regulatory submission for approval.
Cognoptix is creating and developing a simple, innovative non-invasive eye scanning test for the early detection and diagnosis of Alzheimer’s Disease uniquely detecting amyloid in the lens of the eye. A widely accessible and easy to use diagnostic is particularly urgent and necessary now as new disease modifying therapies (DMTs) are poised to come to the market very soon. These DMTs require amyloid detecting diagnostics that function as companion diagnostics.
Cognoptix’s technology consists of a laser eye scanning device combined with an ophthalmic ointment which specifically identifies Alzheimer’s related amyloid proteins found in the lens of the eye. The technology allows for the amyloid in the lens of the eye to be detected early.
As the company develops its diagnostic platform it has demonstrated success in two proof of concepts clinical studies. The company is planning to go into pivotal studies shortly– Cognoptix’s goal is to provide clinicians with a reliable, inexpensive and widely available test that can be performed quickly and accurately by a general practitioner in an office setting, to enable swift intervention and ongoing monitoring of patients.
It is the mission of Cognoptix to help taking the detection of people at risk of Alzheimer’s mainstream. The company’s stand-out senior management team has built a world-renowned scientific advisory board and senior consultant team, bringing together top experts in the AD, neurocognition, clinical trials and research from across the country. Recently selected to be part of the prestigious Framingham Heart Study, Cognoptix aims to expand collaboration with others in the healthcare diagnostic, biotech, and medical device industries.
The company is raising a $15m Series B for funding of its pivotal trial. Approval of the Sapphire II system for amyloid is expected in 2023.
Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on Natural Killer (NK) cell biology and applies precision engineering to induced pluripotent stem cells (iPSCs) to develop the safest, most effective, most broadly-available off-the-shelf Natural Killer cell therapy as a first line of defense against cancer. Cytovia’s proprietary multi-specific antibody platform has been customized to engage and activate NK Cells at the tumor site. Both platforms offer optionality to clinicians and can also be used synergistically. Cytovia’s R&D laboratories and GMP manufacturing facility are augmented by scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, STC Biologics, and the University of California San Francisco (UCSF).
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies. https://www.markertherapeutics.com/
STALICLA is a Biotech Company developing a first-in-class precision medicine platform to accelerate drug development for patients with Neurodevelopmental Disorders (NDDs). STALICLA is using computational systems biology tools to characterize correlations between NDD phenotypes, gene expression in relevant molecular pathways and treatment response. First focus of development has been Autism Spectrum Disorder (ASD). Today, patients diagnosed with ASD account for 1-1.5% of the world population. The condition remains a high unmet medical need. In its Geneva and Barcelona units, STALICLA has assembled a world-class team of drug developers and computational biologists. The Company is recognized as a disruptive player, using its DEPIv3 innovative AI platform. DEPIv3 integrates domain specific large-scale genetic, molecular, pharmacological and clinical data to define patient subgroups and to identify personalized treatments. It is the first time that such technologies have been utilized within for NDDs with the potential to change the direction of the specialty. DEPIv3 has already proven successful in expediting and de-risking drug development for a first subgroup of patients with Autism and identifying two additional subgroups. STALICLA’s first therapeutic package - STP1 - addresses this first distinct subgroup of ASD patients - ASD Phenotype 1- estimated to 1.5 - 2M people in the EU and North America. Clinical entry for STP1 is planned in Q1 2020. ASD Phenotype 1 patient cells have been characterized at molecular level, revealing a ‘fingerprint’ specific to this subgroup of patients with ASD and allowing the development of a Companion Diagnostic tool. To support its platform and pipeline development, STALICLA has developed a network of top-tier research and clinical partners in the US. This has enabled STALICLA to gather one of the largest Autism patients Electronic Health Records database to date. STALICLA is currently scaling up DEPIv3 to advance new pipelines for additional groups of patients with NDDs.
Syneos Health™ is an end-to-end, fully integrated biopharmaceutical solutions company that works differently. At Syneos Health, all the disciplines involved in bringing new therapies to market, from clinical to commercial and consulting, work together to create customer success. Our unique Biopharmaceutical Acceleration Model (BAM) delivers value across the small to mid-size to large customer continuum. We are uniquely positioned to bring into sharp focus the issues that matter most to biotech companies and investors through the breadth and depth of our network, and access to the expertise that the wider Syneos Health organization offers. At Syneos Health, clinical, commercial and consulting live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster. https://www.syneoshealth.com/
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARC’s or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium’s lead application for our ARC’s is targeted conditioning, which is intended to selectively kill patient’s cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies. With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, Iomab-B is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. Beyond Iomab-B, we are developing a multi-disease, multi-target pipeline of clinical-stage ARC’s targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including AML or Acute Myeloid Leukemia, MDS or Myelodysplastic Syndrome MM or Multiple Myeloma. Underpinning our clinical programs is our proprietary AWE or Antibody Warhead Enabling technology platform. This is where our intellectual property portfolio of over 100 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARC’s and ARC combinations to bolster our pipeline and for strategic purposes. Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc.
Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that control mRNA translation as a new strategy against hard and undruggable targets in many diseases.
Anima’s proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes. The fully automated high-throughput screening system discovers small molecules that modulate the light, as they decrease or increase the target protein’s production. The platform integrates proprietary technologies in biology, bioinformatics, image analysis, big data analysis and artificial intelligence algorithms in a cloud computing software architecture.
Anima is developing an internal pipeline across multiple therapeutic areas with high unmet need and hard targets. Current programs are in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (Respiratory Syncytial Virus – interfering with viral protein synthesis), Oncology (C-Myc translation inhibitors), Huntington's disease (monitoring mutant Huntingtin translation pausing) and Repeat Associated Diseases (translation malfunctions).
Anima’s Translation Control Therapeutics platform is strategically designed for partnering with Pharma. The power of Anima’s approach was solidified with a $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Anima’s technology has been further validated by 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations. https://www.animabiotech.com/
Avectas is a cell engineering business developing a unique delivery technology platform to enable the ex-vivo manufacture of our partners' gene-modified cell therapy products, which will retain high in-vivo functionality. Our vision is to be the leading non-viral cell engineering technology provider, integrated into manufacturing processes for multiple autologous and allogeneic therapies. Avectas’ technology, Solupore®, delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of primary cell types including T cells for immuno-oncology and gene editing applications.
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The Company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.”
Bone Therapeutics is a listed, clinical-stage, orthopaedic biotech company committed to rebuilding lives of patients suffering from debilitating bone and joint conditions.
Leveraging its extensive expertise in bone physiology and patented manufacturing technology, Bone Therapeutics is developing a unique, commercially ready, allogeneic bone cell therapy platform, ALLOB, and an off-the-shelf protein solution for osteoarthritis pain, JTA-004, which are designed to offer patients and physicians best-in-class treatment options, superior to existing orthopaedic care.
In Phase II-III clinical development, Bone Therapeutics’ advanced product portfolio targets large orthopaedic conditions with high unmet needs, such as knee osteoarthritis, unhealed fractures and spinal fusion.
Context Therapeutics Inc., is a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The company’s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Context is headquartered in Philadelphia, PA.
Dyve is a clinical stage biotech company with its lead asset, DYV700, currently completing a 20-center, 100-patient, Phase 2 clinical study for the treatment of acute gout. Dyve’s transdermal delivery science platform overturns the traditional limitations of administering therapies. It combines the fast onset of action of an injection with the extended duration and bioavailability of an oral pill – creating ideal PK/PD parameters and an optimal drug profile. Dyve has a robust internal pipeline of novel drugs and a research collaboration in place with a Top 10 Pharmaceutical Company on a separate set of target NCEs.
EIP Pharma is a leading CNS therapeutics-directed clinical stage pharmaceutical company with a scientific focus on the critical pathogenic drivers of early-stage neurodegenerative disease. We are developing neflamapimod, a potent first-in-class oral ATP-competitive inhibitor of p38α kinase, that is ready for late-stage development in Alzheimer’s disease (AD). Mechanistic studies have demonstrated that inhibition of p38α kinase activity targets a critical convergence point within neurons that mediates the toxicity of the major pathogenic drivers (amyloid-beta, tau, neuroinflammation) of AD and related dementias. Preclinical data has shown positive effects of neflamapimod on both functional (cognitive) and neurodegenerative outcomes. The company presented phase 2b clinical trial data at the Clinical Trials in Alzheimer's Disease (CTAD) meeting in December 2019 that demonstrated target engagement and proof-of-mechanism for neflamapimod treatment through a positive, statistically significant reduction relative to placebo in CSF markers of neurodegeneration and synaptic dysfunction. Phase 2 studies in Huntington’s disease (HD) and Dementia of Lewy bodies (DLB) are currently enrolling patients and are due to read-out in Q3'2020. Neflamapimod was licensed in 2014 from Vertex Pharmaceuticals, who had developed neflamapimod through to early phase 2 clinical trials in non-CNS disease indications and had completed a full chronic toxicology program. EIP Pharma is led by a top-tier management team that has a track record in developing major, innovative medicines and with that success build and grow companies. The founders, the executive chair and CEO, previously had executive management roles at major biopharmaceutical companies (Biogen, Vertex, Shire). https://www.eippharma.com/
Herantis Pharma Plc
Herantis Pharma is a publicly listed (HRTIS and HRNTS) drug development company aiming to revolutionize the treatment of diseases with unmet clinical needs. Based on leading academic research published in high-impact journals including Nature and Science, the two ongoing clinical development programs explore the potential of our novel drug candidates in Parkinson’s disease.
For Parkinson’s disease, our neuroprotective and neurorestorative drug candidate CDNF is intended to become the first disease-modifying treatment with further potential in other neurodegenerative diseases.
Parkinson’s disease remain a condition in which current treatments only address symptoms and therefore do not enable long-term improvement for patients. To successfully move forward our vision of breaking the boundaries of standard therapeutic approaches, Herantis has assembled a group of highly experienced professionals for the team and Board of Directors.
Immunicum is a clinical-stage biotech developing allogeneic, off-the-shelf cell therapies for solid tumors. Our lead product ilixadencel has now completed a Phase II controlled study in kidney cancer, which showed deeper and more durable tumor responses (including complete responses) and a difference in median survival as compared to control arm. Based on these results, in June 2020, the FDA granted an RMAT Designation, similar to a Breakthrough Therapy Designation. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.
Microbiotica is founded on ground-breaking microbiome science from the Wellcome Sanger Institute. The company has unique capabilities to isolate all gut bacteria from any human and to identify gut bacterial signatures linked to patient phenotype from large clinical datasets with unprecedented precision. It is initially progressing live bacterial therapeutics and biomarkers in IBD and I-O, driven by best-in-class clinical datasets. The company has a $534m commercial partnership with Genentech, and clinical collaborations with Univ of Adelaide, Cambridge University Hospitals and Cancer Research UK.
NOXXON’s oncology-focused pipeline acts by neutralizing chemokines in the tumor micro-environment (TME). NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact.
ORYZON is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology.
Our business model is to develop our proprietary drug candidates through clinical Phase II, at which point we decide on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization.
ORYZON has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks.
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide.
Oxurion is aiming to build the leading global franchise in the treatment of DME, based on the successful development of its two novel therapeutics: - THR-149 - THR-687
Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR
QurAlis is bringing hope to the ALS community by developing breakthrough precision medicines for this devastating disease.
Our stem cell technologies generate proprietary human neuronal models that enable us to more effectively discover and develop innovative therapies for genetically validated targets. We are advancing three antisense and small molecule programs addressing sub-forms of the disease that account for the majority of patients. Together with a world-class network of thought leaders, drug developers and patient advocates, our team is rising to the challenge of conquering ALS.
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects 40,000 people in France and nearly 2 million worldwide. SparingVision is a spin-off of the Paris Vision Institute. Bpifrance, Foundation Fighting Blindness (US) and Voir & Entendre Foundation invested €15.5 million in the company. SparingVision was laureate and Grand Prize of i-Lab 2017, the National Contest for the Creation of Innovative Companies, and is part of the first selection of companies of Hub Heath Tech launched by Bpifrance in December 2017. SparingVision has been created on strong expertise and technology from Institut de la Vision in Paris. SparingVision' therapeutic approach is to prevent and slow down progression of cones degeneration, first step in retinitis pigmentosa evolution, leading to total death of all the photoreceptors and blindness. The innovative approach is therefore independent of causal mutation and applies to advanced stages of the condition. SparingVision’ lead product candidate, begins preclinical trial. SparingVision is supported by Foundation Fighting Blindness, a non-profit research center based in USA, as well as an international Scientific Advisory Board.
Versameb AG is a privately held company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression and cellular targeting, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with a single molecular construct. Based in Basel, Switzerland and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient.
Versameb’s proprietary technology platform, VERSagile, optimizes the application of functional mRNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve to date.
Versameb was part of BaseLaunch, the Basel-Area based incubator and accelerator that supports early-stage ventures developing cutting-edge therapeutics.
Anocca is a privately held medical biotechnology company dedicated to establishing an engineered human cell-based discovery, validation and clinical development platform for deciphering T-cell immunity and delivering next generation T-cell therapies. Based in modern facilities in Södertälje, near Stockholm, Sweden, Anocca has built up a talented team of almost 50 scientists from 23 different nations.
The fully operational industrialized platform comprises integrated cell biology and genetics modules and is capable of rapidly and systematically identifying and validating antigen/T-cell receptor (TCR) combinations to access a virtually unlimited target space. The platform is underpinned by proprietary, purpose-built IT infrastructure and data handling capability. Alongside, Anocca has established an advanced GMP manufacturing facility to produce cellular therapeutics for clinical use.
Anocca is leveraging its technology platform and manufacturing capabilities to deliver candidates for TCR-modified T-cell therapies in highly segmented patient populations within oncology.
Complementary clinical programs with a fully individualized strategy for targeting the unique aspects of an individual’s cancer cells will also be deployed. Anocca’s technologies will enable the delivery of these transformative cellular therapies for a wide range of cancer types, in almost any individual.
Beyond oncology, Anocca’s platform has been designed for broad use in distinct applications. In particular, this includes the design and deployment of prophylactic vaccines for a wide range of pathogens and for tolerization of autoimmunity.
Apaxen is developing small molecule MIF-inhibitors for treatment of Pulmonary Arterial Hypertension (PAH) and other chronic inflammatory diseases. Lead compound MFC-1040 is expected to start clinical testing in Q1 2022.
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development. insphero.com
PDC*line Pharma SA
PDC*line Pharma is a clinical-stage spin-off of the French Blood Bank (EFS) that develops a new class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a robust preclinical package and a first-in-human phase Ib in melanoma, PDC*line Pharma has initiated a clinical development in lung cancer with a new candidate (PDC*lung) and neoantigens (PDC*Neo). PDC*line Pharma comprises a team of 25 persons based in Belgium (Liège, headquarters) and France (Grenoble). The company has raised nearly €31.5 M (19,5 M€ in equity and 12 M€ of non-dilutive money). The last round has been led by the Asian leading VC KIP (Ko-rean Investment Partners). In March 2019, PDC*line Pharma granted an exclu-sive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercializa-tion of PDC*lung cancer vaccine for lung cancer. The total deal value is €108M (123M$) plus significant tiered royalties on net sales in Asia.
TOLLYS is developing best in class specific TLR3 agonists in the field of immuno-oncology. TOLLYS was founded in 2015 by senior scientists from the leading European Cancer Research Center of Lyon in France and the Centre Léon Bérard.
They discovered the ability of TLR3 agonists to induce a direct and immunogenic tumor cell death in addition to their immunostimulant properties (activator of antigen presenting cells) and to their ability to induce a switch of the tumoral micro-environment. They postulated that the combination of these 3 actions will lead to an intense activation and recruitment of patient tumor specific cytotoxic T lymphocytes (CTL) in the tumor bed, resulting in anti-tumor effects and in-situ auto vaccination against recurrences.
Former heterogenous dsRNA with TLR3 agonist properties, have demonstrated clinical efficacy in the past in TLR3+ breast cancer patients with a good tolerance but never reached the market due to a lack of product homogeneity. TOLLYS discovered and patented in 2018 a new family of TLR3 agonists, among which TL-532 is the lead candidate, a dsRNA perfectly defined in sequence and length.
TL-532 showed efficacy in preclinical models to induce anti-tumor response and prevention of recurrences with a good tolerability and a synergistic effect with immune checkpoint inhibitors. TOLLYS plans to enter clinical trials with TL-532 in 2021 in Non Muscle Invasive Bladder cancer (NMIBC) unresponsive to BCG treatment, a high medical need indication with a potential for accelerated market approval. TL-532 has a broad indication potential since TLR3 is expressed in a variety of cancers.
Invasight is a Swiss-based early-clinical stage biotech start-up. Our breakthrough technology, ACINDA accelerates drug discovery and enables design of specific protein-protein interaction inhibitors (PPIs) for non-traditional intercellular protein targets, which cause cancer cell invasion. Our first-in-class PPIs combine potent anti-tumour activity with a favourable safety profile for patients with invasive cancers. The most advanced of these first-in-class, protein-protein interaction inhibitors is F2i, a inhibitor of pro-invasive FGFR signalling. F2i is currently in 'pre-clinical' validation stage of drug development.